Edition:
United States

Innoviva Inc (INVA.OQ)

INVA.OQ on NASDAQ Stock Exchange Global Select Market

16.23USD
19 Apr 2018
Change (% chg)

-- (--)
Prev Close
$16.23
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
294,356
52-wk High
$17.98
52-wk Low
$11.06

Select another date:

Tue, Feb 13 2018

BRIEF-Sarissa Capital Reconstitutes Innoviva Board

* JULES HAIMOVITZ, SARAH SCHLESINGER, AND MARK DIPAOLO WILL BE ADDED TO INNOVIVA BOARD Source text for Eikon:

BRIEF-Innoviva Enteres Into Agreement With Sarissa Capital Management

* INNOVIVA INC - ENTERED INTO AN AGREEMENT WITH SARISSA CAPITAL MANAGEMENT LP, AND CERTAIN OF ITS AFFILIATES

Drug company Innoviva settles with activist hedge fund Sarissa: sources

U.S. respiratory drug company Innoviva Inc has reached a settlement with activist hedge fund Sarissa Capital Management LP to replace its board of directors and remove the threat of a new proxy contest, people familiar with the matter said on Monday.

Drug company Innoviva settles with activist hedge fund Sarissa -sources

Feb 12 U.S. respiratory drug company Innoviva Inc has reached a settlement with activist hedge fund Sarissa Capital Management LP to replace its board of directors and remove the threat of a new proxy contest, people familiar with the matter said on Monday.

BRIEF-Innoviva Reports Q4 Adj Earnings Per Share $0.55

* INNOVIVA REPORTS RECORD FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Innoviva Appoints Eric D'Esparbes As Co's Interim Principal Executive Officer

* INNOVIVA SAYS ON FEB 7, CO ANNOUNCED APPOINTMENT OF ERIC D'ESPARBES AS CO'S INTERIM PRINCIPAL EXECUTIVE OFFICER, EFFECTIVE FEB 6 - SEC FILING

BRIEF-GSK and Innoviva announce positive data from COPD study

* GSK STUDY DEMONSTRATES SUPERIORITY OF ANORO ELLIPTA TO STIOLTO RESPIMAT IN IMPROVING LUNG FUNCTION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE

BRIEF-Innoviva reports Q3 adj earnings $0.31/shr

* Innoviva reports third quarter 2017 financial results and provides business updates

Select another date: